VivoSeq
Cardiovascular

Coronary Artery Disease

191

Pipeline Programs↗

59

Active Trials↗

76

Companies Involved↗

Coronary Artery Disease is a highly competitive landscape with 191 programs across 76 companies. The most active players are Eastern Cooperative Oncology Group, Omnivium, Gilead. 87 therapies are approved with 27 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

81/100

Pipeline Velocity

57/100

Mech. Concentration

7/100

Completion Rate

88/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

1 program

Phase 1O

Omnivium

1 program

Phase 1Gilead logo

Gilead

1 program

Phase 2Eisai logo

Eisai

1 program

Phase 2A

Anthera Pharmaceuticals

1 program

Phase 2L

Lisata Therapeutics, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical37

Dabigatran

Boehringer Ingelheim

Montelukast

Organon and Co

Alirocumab

Regeneron

Abciximab

Boehringer Ingelheim

Pitavastatin

Medicure

Phase 112

Filgrastim

Eastern Cooperative Oncology Group

Vericiguat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Isosorbide Mononitrate

Omnivium

Bradykinin

Vanderbilt University

Cardiopet

Fluoropharma, Inc.

Phase 228

Levosimendan

Orion Corporation, Orion Pharma

Nitroglycerin

Viatris Specialty LLC

Nicorandil

Merck & Co.

Sapropterin Dihydrochloride

BioMarin Pharmaceutical

Amiloride

Padagis LLC

Phase 327

Exenatide

AstraZeneca

Glutamine

Sanofi

Ridaforolimus

Merck & Co.

Quercetin

Mayo Clinic

Inclisiran

Novartis

Approved87

Tirzepatide

Eli Lilly

Clopidogrel

Sanofi

Tranexamic Acid

Amring

Cilostazol

Otsuka

Propofol

Fresenius Kabi Oncology Ltd.

Analysis

Modality Breakdown

94%

Small molecule

197 of 210 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody42%Peptide42%Protein / enzyme2<1%RNA therapy2<1%Vaccine1<1%

Small molecule leads; the ring shows all 210 classified programs, each share of the total. Modality classified for 98% of 224 pipeline programs.

Analysis

Trial Status

243

clinical trials

Completed116 · 48%
Unknown status51 · 21%
Recruiting29 · 12%
Active, not recruiting14 · 6%
Terminated13 · 5%
Not yet recruiting13 · 5%
Other7 · 3%

Clinical Trials

Trial Activity

243 trials

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease
Recruiting·UUniversity of Virginia·Phase 1·NCT05762952·40 enrolled
Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention
Recruiting·AAZ Sint-Jan AV·Phase 3·NCT06095765·2,770 enrolled
Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease
Recruiting·XXijing Hospital·Phase 2·NCT06572267·18 enrolled
A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT ReductioN of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease
Recruiting·KKorea University Anam Hospital·Phase 4·NCT05427786·460 enrolled
Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes
Recruiting·National Institute of Cardiology, Warsaw, Poland·Phase 4·NCT07254572·300 enrolled
The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
Recruiting·—·Phase 4·NCT06606821·124 enrolled
The Prevent Coronary Artery Disease Trial
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 3·NCT06494501·1,600 enrolled
Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention
Recruiting·SSaint Vincent's Hospital, Korea·Phase 4·NCT06186037·6,356 enrolled
Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease
Recruiting·CChina National Center for Cardiovascular Diseases·Phase 4·NCT06917664·220 enrolled
Group Singing (Hybrid Format) or Solo Singing in Older Adults With Coronary Artery Disease: A Feasibility Study
Recruiting·MMedical College of Wisconsin·Preclinical·NCT07355192·32 enrolled
A Phase I, Randomized, Double-Blind, Adaptive, Placebo-Controlled, Single- Ascending Dose and Multiple-Ascending Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of RO7763505 Following Oral Administration in Healthy Participants and Patients With Stable Coronary Artery Disease
Recruiting·Roche logoRoche·Phase 1·NCT07495813·196 enrolled
Coronary Calcified Nodule Management With Rotational Atherectomy Plus Shockwave Intravascular Lithotripsy vs. Intravascular Lithotripsy Alone: A Prospective, Randomized Trial (NODULE-SHOCK)
Recruiting·—·Preclinical·NCT07000045·120 enrolled
The Impact of Procedural Complications on Long-Term Mortality in Complex Coronary Interventions: The Multicenter COMPLEX-ANATOLIA Study
Recruiting·Istanbul Mehmet Akif Ersoy Educational and Training Hospital·N/A·NCT07202754·20,000 enrolled
BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Resorbable MAGnesium Scaffold (Freesolve) in the Treatment of Subjects With Long de Novo Lesions in Native Coronary Arteries: BIOMAG-LL
Recruiting·BBiotronik, Inc.·Preclinical·NCT07091682·100 enrolled
Randomized Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions
Recruiting·FFundación EPIC·Preclinical·NCT06736899·200 enrolled
Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)